Next Article in Journal
GDF-15 Inhibits ADP-Induced Human Platelet Aggregation through the GFRAL/RET Signaling Complex
Next Article in Special Issue
2α-Substituted Vitamin D Derivatives Effectively Enhance the Osteoblast Differentiation of Dedifferentiated Fat Cells
Previous Article in Journal
Evaluation of the Mechanisms Involved in the Development of Bladder Toxicity following Exposure to Occupational Bladder Cancer Causative Chemicals Using DNA Adductome Analysis
Previous Article in Special Issue
Characterization of Rickets Type II Model Rats to Reveal Functions of Vitamin D and Vitamin D Receptor
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Efficient Stereo-Selective Fluorination on Vitamin D3 Side-Chain Using Electrophilic Fluorination

Faculty of Pharmaceutical Sciences, Teikyo University, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan
*
Author to whom correspondence should be addressed.
Biomolecules 2024, 14(1), 37; https://doi.org/10.3390/biom14010037
Submission received: 6 December 2023 / Revised: 21 December 2023 / Accepted: 22 December 2023 / Published: 26 December 2023
(This article belongs to the Special Issue Biochemistry and Molecular Biology of Vitamin D and Its Analog II)

Abstract

:
Our research regarding side-chain fluorinated vitamin D3 analogues has explored a series of efficient fluorination methods. In this study, a new electrophilic stereo-selective fluorination methodology at C24 and C22 positions of the vitamin D3 side-chain was developed using N-fluorobenzenesulfonimide (NFSI) and CD-ring imides with an Evans chiral auxiliary (26,27,30).

1. Introduction

Regio- and stereo-selective fluorination of the vitamin D3 side-chain is one of the efficient methods used to modulate biological activities, such as binding affinity to the vitamin D receptor (VDR), transactivation activity through the VDR, and metabolic stability against CYP24A1 [1]. We have reported the regio- and stereo-selective fluorination of the CD-ring side-chain starting from the Inhoffen–Lythgoe diol (1) and constructed C26,27-fluoro-CD-rings (2–4) [2,3], C24-fluoro-CD-rings (5–7) [4,5], C23-fluoro-CD-rings (8–10) [6,7], and C22-fluoro-CD-rings (11–13) [8] (Figure 1) to create a chemical library of side-chain fluorovitamin D3 analogues using a convergent method (Scheme 1) [9,10,11].

1.1. Previous Studies of C24-Stereoselective Fluorination

On the vitamin D3 side-chain, the C24 position is an important site for metabolic inactivation via CYP24A1 hydroxylation [12,13,14]. Therefore, structural modifications, especially fluorination and difluorination, of the C24 position have been actively investigated [15,16,17,18,19,20,21,22,23,24,25].
We previously reported the stereo-selective fluorination method at the C24 position of the CD-ring side-chain for stereo-selective synthesis of (24R)-fluoro-25-hydroxyvitamin D3 and its 24S isomer [5]. The key step for introducing the C24-fluoro unit was achieved via osmium-catalyzed diastereoselective dihydroxylation followed by deoxy-fluorination reactions. However, multi-step synthesis was required (13 steps), and harmful osmium and excess amounts of the fluorinating reagent, DAST, were used in this synthetic route (Scheme 2).

1.2. Previous Studies of C22-Stereoselective Fluorination

Until 2023, there was only one example of 22-fluorovitamin D synthesis, and the stereochemistry of C22 was unknown [26]. We recently reported the first stereo-selective fluorination at the C22 position of the CD-ring side-chain and synthesis of (22R)- and (22S)-fluoro-25-hydroxyvitamin D3 [8]. However, multiple synthetic steps were required, including separation of the diastereomer mixture of C22-allylalcohols (19,20) and the deoxyfluorination step using DAST, resulting in low overall yields (Scheme 3).
In the report [8], we also developed an alternative C22-fluorination methodology using a cationic fluorination reaction between the methyl ester (23) and N-fluorobenzenesulfonimide (NFSI) under basic conditions. However, this route yielded only the (22R)-fluoro product (21); efficient cationic fluorination of the (22S)-fluoro counterpart to yield the (22R)-CD-ring (11) has yet to be explored (Scheme 4).
To overcome these drawbacks in order to introduce C24- and C22-monofluoro moieties, here we describe an alternative stereo-selective fluorination methodology at these positions via electrophilic fluorination using an Evans chiral auxiliary-based aldol reaction with NFSI [27,28,29].
The retrosynthetic paths are shown in Scheme 5. Evans oxazolidinone ligands could be introduced to the side-chain carboxylic acids (28,31), which were synthesized from the Inhoffen–Lythgoe diol (1), and NFSI could be used as a cationic fluorination reagent in the presence of lithium hexamethyldisilazide (LHMDS).

2. Results and Discussion

2.1. Synthesis of 24-Fluoro-CD-Rings (5,6) via Electrophilic Fluorination

The synthetic route of the 24-fluoro-CD-rings (5,6) is illustrated in Scheme 6. We synthesized methyl ester (32) from the Inhoffen–Lythgoe diol (1) in three steps [30], and hydrolysis of 32 afforded the corresponding carboxylic acid (28) [31], which was subsequently converted to N-acyloxazolidinones (26,27) via acid chlorides. The C24-position was effectively fluorinated in a high diastereoselective manner to yield (24R)-product 24 from 26 and (24S)-product 25 from 27, respectively. Displacement of the oxazolidinone ligand to 26,27-dimethyl units with the 25-hydroxy group using an excess amount of methyl magnesium chloride successfully proceeded with preservation of the stereochemistry at the C24-position, and removal of the silyl protective group under acidic conditions yielded the target (24R)-fluoro-CD-ring 5 (62% in 8 steps) and (24S)-fluoro-CD-ring 6 (53%).

2.2. Synthesis of (22R)-Fluoro-CD-Ring (11) via Electrophilic Fluorination

The synthetic route to the (22R)-fluoro-CD-ring (11) started from carboxylic acid (31), which was readily available from the Inhoffen–Lythgoe diol in five steps [32]. This was converted to amide (30) followed by fluorination at the C22-position using NFSI in the presence of LHMDS to give the desired (22S)-fluoro-CD-ring (29) as a major product, along with (22R)-fluoro-CD-ring (33) at a ratio of 1.4:1. After separating 29 and 33 using silica gel column chromatography, they were converted to the corresponding Weinreb amides (34,35), which were the synthetic intermediates of C22-fluoro-CD-rings 11 and 12 [8], using methoxy(methyl)amine hydrochloride and LHMDS in moderate yields and with a rigid stereochemical integrity (Scheme 7).

3. Conclusions

In conclusion, we developed an improved stereo-selective fluorination method at C24 and C22 positions to synthesize C24- and C22-fluoro-CD-rings utilizing an Evans chiral auxiliary for a cationic fluorination reaction as a key step. The side-chain carboxylic acids (28,31) were prepared from the Inhoffen–Lythgoe diol. These synthetic routes are more efficient than previous ones reported regarding both total yields and reaction steps.
  • Experimental Section
1H and 13C NMR spectra were recorded on JEOL AL-400 NMR (400 MHz) and ECP-600 NMR (600 MHz) spectrometers (Tokyo, Japan). 1H NMR spectra were referenced using (CH3)4Si (δ 0.00 ppm) or CHCl3 (δ 7.26 ppm) as an internal standard. 13C NMR spectra were referenced using deuterated solvent (δ 77.0 ppm for CDCl3). IR spectra were recorded using a JASCO FT-lR-800 Fourier transform infrared spectrophotometer (Tokyo, Japan). High-resolution mass spectra were obtained using a SHIMADZU LCMS-IT-TOF mass spectrometer (Kyoto, Japan) using a positive electrospray ionization (ESI) method. Optical rotations were measured using a JASCO DIP-370 digital polarimeter (Tokyo, Japan). Column chromatography was performed on silica gel 60N (Kanto Chemical Co., Inc., 40–50 μm, Tokyo, Japan) or silica gel 60 (Merck, 0.040–0.063 mm, Tokyo, Japan). All experiments were performed under anhydrous conditions in an atmosphere of argon, unless otherwise stated. Supporting information regarding 1H and 13C NMR spectra of all new compounds (26, 27, 29, 30, and 33) is available via the link in Supplementary Materials.
  • (4R)-3-[(5R)-5-{(1R,3aR,4S,7aR)-4-[(tert-Butyldimethylsilyl)oxy]-7a-methyloctahydro-1H-inden-1-yl}hexanoyl]-4-isopropyloxazolidin-2-one (26)
Carboxylic acid 28 [31] (403.6 mg, 1.05 mmol) was dissolved in thionyl chloride (3.0 mL, 4.97 g, 41.8 mmol) at room temperature, and the solution was refluxed for 1 h 30 min. The mixture was evaporated in vacuo, and the crude acyl chloride was used for the next reaction without further purification.
nBuLi (1.59 M in hexane, 5.3 mL, 8.40 mmol) was added to a precooled solution of (R)-4-isopropyloxazolidinone (1.09 g, 8.40 mmol) in THF (20 mL) at −78 °C, and the mixture was stirred at the same temperature for 10 min. The above acyl chloride in THF (3 mL) was added to the solution and stirred at the same temperature for 10 min. After the reaction was quenched with H2O and saturated aqueous NH4Cl at room temperature, the mixture was extracted with EtOAc three times. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified via flash column chromatography on silica gel (hexane:EtOAc = 3:1) to obtain 26 (513.6 mg, 99%, in 2 steps) as a colorless oil.
26: [α] D27 + 6.1 (c 2.01, CHCl3); IR (neat) 1786, 1704, 1383, 1252, 1208, 1085, 1023, 841 cm−1; 1H NMR (600 MHz, CDCl3) δ –0.02 (s, 3H), –0.01 (s, 3H), 0.86–0.91 (m, 21H), 1.02–1.12 (m, 3H), 1.18–1.25 (m, 2H), 1.29–1.44 (m, 5H), 1.47–1.56 (m, 2H), 1.64–1.66 (m, 1H), 1.69–1.83 (m, 3H), 1.92–1.95 (m, 1H), 2.34–2.39 (m, 1H), 2.80–2.95 (m, 2H), 3.97–3.99 (m, 1H), 4.18–4.27 (m, 2H), 4.42 (dt, J = 3.0, 8.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ –5.2, –4.8, 13.7, 14.6, 17.6, 18.0, 18.0, 18.5, 21.0, 23.0, 25.8, 27.2, 28.4, 34.4, 35.1, 35.2, 35.9, 40.7, 42.1, 53.0, 56.5, 58.4, 63.3, 69.4, 154.0, 173.4; HRMS (ESI+) calcd for C28H51NO4SiNa [M+Na]+ 516.3480, found 516.3489.
  • (4S)-3-[(5R)-5-{(1R,3aR,4S,7aR)-4-[(tert-Butyldimethylsilyl)oxy]-7a-methyloctahydro-1H-inden-1-yl}hexanoyl]-4-isopropyloxazolidin-2-one (27)
Carboxylic acid 28 (606.2 mg, 1.58 mmol) was dissolved in thionyl chloride (3.4 mL, 5.6 g, 47.0 mmol) at room temperature, and the solution was refluxed for 1 h 30 min. The mixture was evaporated in vacuo, and the crude acyl chloride was used for the next reaction without further purification.
nBuLi (1.59 M in hexane, 5.9 mL, 9.42 mmol) was added to a precooled solution of (S)-4-isopropyloxazolidinone (1.24 g, 9.60 mmol) in THF (20 mL) at −78 °C, and the mixture was stirred at the same temperature for 10 min. The above acyl chloride in THF (4 mL) was added to the solution and stirred at the same temperature for 20 min. After the reaction was quenched with H2O and saturated aqueous NH4Cl at room temperature, the mixture was extracted with EtOAc three times. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified via flash column chromatography on silica gel (hexane:EtOAc = 3:1) to obtain 27 (729.5 mg, 93%, in 2 steps) as a colorless oil.
27: [α] D27 + 78.4 (c 1.58, CHCl3); IR (neat) 1786, 1704, 1387, 1255, 1208, 1089, 1027, 841 cm−1; 1H NMR (600 MHz, CDCl3) δ –0.02 (s, 3H), 0.00 (s, 3H), 0.86–0.92 (m, 21H), 1.00–1.11 (m, 3H), 1.19–1.25 (m, 2H), 1.29–1.44 (m, 5H), 1.49–1.57 (m, 2H), 1.61–1.83 (m, 4H), 1.92–1.95 (m, 1H), 2.33–2.40 (m, 1H), 2.76–2.99 (m, 2H), 3.97–3.99 (m, 1H), 4.18–4.27 (m, 2H), 4.42 (dt, J = 3.3, 8.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ –5.2, –4.8, 13.7, 14.6, 17.6, 18.0, 18.0, 18.5, 21.0, 23.0, 25.8, 27.2, 28.4, 34.4, 35.1, 35.2, 36.0, 40.7, 42.1, 53.0, 56.5, 58.3, 63.3, 69.4, 154.1, 173.5; HRMS (ESI+) calcd for C28H51NO4SiNa [M+Na]+ 516.3480, found 516.3495.
  • (1R,3aR,4S,7aR)-1-[(2R,5R)-5-Fluoro-6-hydroxy-6-methylheptan-2-yl]-7a-methyloctahydro-1H-inden-4-ol (5)
To a solution of 26 (168.9 mg, 0.34 mmol) in THF (2 mL) and hexamethylphosphoric triamide (HMPA) (200 μL) was added LHMDS (lithium hexamethyldisilazide) (359 μL, 1 M THF solution, 0.36 mmol) at −78 °C, the mixture was stirred at the same temperature for 10 min, and N-fluorobenzenesulfonimide (NFSI) (117.8 mg, 0.37 mmol) was added. After being stirred at the same temperature for 40 min, the reaction mixture was quenched with H2O and saturated aqueous NH4Cl at −78 °C. The mixture was extracted with EtOAc three times. The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. Crude 24 was used for the next reaction without further purification.
To a solution of the above crude 24 in THF (10 mL) was added MeMgCl (1.14 mL, 3.0 M THF solution, 3.42 mmol) at 0 °C, and the mixture was stirred at 0 °C for 10 min. After the reaction was quenched with H2O, the mixture was extracted with EtOAc three times. The organic layer was washed with saturated aqueous NH4Cl, dried over Na2SO4, filtered, and concentrated. The crude residue was used for the next reaction without further purification.
To the above crude residue in MeOH (15 mL) was added p-toluenesulfonic acid monohydrate (479.9 mg, 2.52 mmol), and the mixture was stirred at room temperature for 63 h under air. After the reaction was quenched with H2O and saturated aqueous NaHCO3 at room temperature, the mixture was extracted with EtOAc three times. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified via flash column chromatography on silica gel (hexane:EtOAc = 2:1) to obtain 5 (77.5 mg, 75%, in 3 steps) as a white powder. The spectral data matched with those reported in the literature [5].
  • (1R,3aR,4S,7aR)-1-[(2R,5S)-5-Fluoro-6-hydroxy-6-methylheptan-2-yl]-7a-methyloctahydro-1H-inden-4-ol (6)
To a solution of 27 (111.0 mg, 0.23 mmol) in THF (2 mL) and hexamethylphosphoric triamide (HMPA) (200 μL) was added LHMDS (lithium hexamethyldisilazide) (236 μL, 1 M THF solution, 0.24 mmol) at −78 °C, the mixture was stirred at the same temperature for 10 min, and N-fluorobenzenesulfonimide (NFSI) (76.4 mg, 0.24 mmol) was added. After being stirred at the same temperature for 40 min, the reaction mixture was quenched with H2O and saturated aqueous NH4Cl at −78 °C. The mixture was extracted with EtOAc three times. The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. Crude 25 was used for the next reaction without further purification.
To a solution of the above crude 25 in THF (7 mL) was added MeMgCl (0.75 mL, 3.0 M THF solution, 2.25 mmol) at 0 °C, and the mixture was stirred at 0 °C for 10 min. After the reaction was quenched with H2O, the mixture was extracted with EtOAc three times. The organic layer was washed with saturated aqueous NH4Cl, dried over Na2SO4, filtered, and concentrated. The crude residue was used for the next reaction without further purification.
To the above crude residue in MeOH (10 mL) was added p-toluenesulfonic acid monohydrate (558.3 mg, 2.94 mmol), and the mixture was stirred at room temperature for 18 h under air. After the reaction was quenched with H2O and saturated aqueous NaHCO3 at room temperature, the mixture was extracted with EtOAc three times. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified via flash column chromatography on silica gel (hexane:EtOAc = 2:1) to obtain 6 (45.9 mg, 68%, in 3 steps) as a white powder. The spectral data matched with those reported in the literature [5].
  • (4S)-3-[(3R)-3-{(1R,3aR,4S,7aR)-4-[(tert-Butyldimethylsilyl)oxy]-7a-methyloctahydro-1H-inden-1-yl}butanoyl]-4-isopropyloxazolidin-2-one (30)
Carboxylic acid 31 [32] (613.8 mg, 1.73 mmol) was dissolved in thionyl chloride (2.5 mL, 4.12 g, 34.6 mmol) at room temperature, and the solution was refluxed for 1 h 30 min. The mixture was evaporated in vacuo, and the crude acyl chloride was used for the next reaction without further purification.
nBuLi (1.59 M in hexane, 3.3 mL, 5.19 mmol) was added to a precooled solution of (S)-4-isopropyloxazolidinone (673.3 mg, 5.21 mmol) in THF (6 mL) at −78 °C, and the mixture was stirred at the same temperature for 15 min. The above acyl chloride in THF (6 mL) was added to the solution and stirred at the same temperature for 15 min. After the reaction was quenched with H2O and saturated aqueous NH4Cl at room temperature, the mixture was extracted with EtOAc three times. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified via flash column chromatography on silica gel (hexane:EtOAc = 4:1) to obtain 30 (679.3 mg, 84%, in 2 steps) as a colorless oil.
30: [α] D27 +67.9 (c 1.28, CHCl3); IR (neat) 1778, 1700, 1471, 1383, 1259, 1212, 1104, 1019, 960, 849, 779 cm−1; 1H NMR (600 MHz, CDCl3) δ –0.02 (s, 3H), 0.00 (s, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.88 (s, 9H), 0.91 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H), 0.95 (s, 3H), 1.10–1.17 (m, 2H), 1.23–1.27 (m, 1H), 1.32–1.43 (m, 4H), 1.53–1.61 (m, 1H), 1.64–1.68 (m, 1H), 1.76–1.84 (m, 2H), 1.94 (dt, J = 3.0, 12.6 Hz, 1H), 2.03–2.10 (m, 1H), 2.32–2.40 (m, 1H), 2.58 (dd, J = 9.6, 16.2 Hz, 1H), 2.58 (dd, J = 3.6, 15.6 Hz, 1H), 3.99–4.00 (m, 1H), 4.19 (dd, J = 3.3, 9.3 Hz, 1H), 4.25 (t, J = 8.7 Hz, 1H), 4.45 (dt, J = 3.6, 8.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ –5.2, 4.8, 13.8, 14.5, 17.6, 18.0, 19.3, 23.0, 25.8, 27.0, 28.3, 32.6, 23.4, 40.6, 42.0, 42.3, 53.0, 56.9, 58.3, 63.1, 69.4, 154.0, 173.2; HRMS (ESI+) calcd for C26H47NO4SiNa [M+Na]+ 488.3167, found 488.3183.
  • (4S)-3-[(2S,3S)-3-{(1R,3aR,4S,7aR)-4-[(tert-Butyldimethylsilyl)oxy]-7a-methyloctahydro-1H-inden-1-yl}-2-fluorobutanoyl]-4-isopropyloxazolidin-2-one (29) and (4S)-3-[(2R,3S)-3-{(1R,3aR,4S,7aR)-4-[(tert-Butyldimethylsilyl)oxy]-7a-methyloctahydro-1H-inden-1-yl}-2-fluorobutanoyl]-4-isopropyloxazolidin-2-one (33)
To a solution of 30 (207.6 mg, 0.45 mmol) in THF (3 mL) was added LHMDS (lithium hexamethyldisilazide) (472 μL, 1 M THF solution, 0.472 mmol) at −78 °C, the mixture was stirred at 0 °C for 1 h, and N-fluorobenzenesulfonimide (NFSI) (168.6 mg, 0.53 mmol) was added to the mixture at −78 °C. After being stirred at the same temperature for 2 h, the reaction was quenched with H2O and saturated aqueous NH4Cl at −78 °C. The mixture was extracted with EtOAc three times. The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified via flash column chromatography on silica gel (hexane:EtOAc = 2:1) to obtain 29 (108.4 mg, 50%) (less polar) and 33 (74.9 mg, 35%) (more polar), each as a colorless oil.
29: [α] D27 + 83.1 (c 1.08, CHCl3); IR (neat) 1786, 1718, 1384, 1256, 1201, 1025, 834 cm−1; 1H NMR (600 MHz, CDCl3) δ –0.02 (s, 3H), 0.00 (s, 3H), 0.88 (s, 9H), 0.89 (d, J = 7.2 Hz, 3H), 0.92 (s, 3H), 0.94 (d, J = 6.6 Hz, 3H), 1.14–1.39 (m, 9H), 1.52–1.67 (m, 3H), 1.74–1.94 (m, 3H), 2.08–2.18 (m, 1H), 2.51–2.56 (m, 1H), 3.98–4.00 (m, 1H), 4.29 (dd, J = 1.8, 9.0 Hz, 1H), 4.35 (t, J = 8.7 Hz, 1H), 4.38–4.40 (m, 1H), 5.74 (dd, J =2.7, 47.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ –5.2, –4.8, 13.3, 14.4, 17.2 (d, J = 2.9 Hz), 17.5, 18.0, 18.0, 23.5, 25.8, 26.9, 28.0, 34.3, 40.1, 40.2, 40.3, 42.9, 51.6, 52.3, 59.1, 64.0, 69.3, 93.8 (d, J = 180.9 Hz), 153.5, 170.1 (d, J = 23.1 Hz); HRMS (ESI+) calcd for C26H46NO4FSiNa [M+Na]+ 506.3072, found 506.3075.
33: [α] D27 +1.2 (c 0.57, CHCl3); IR (neat) 1790, 1718, 1391, 1260, 1204, 1097, 1025, 978, 842, 774 cm−1; 1H NMR (600 MHz, CDCl3) δ –0.01 (s, 3H), 0.01 (s, 3H), 0.87 (d, J = 7.2 Hz, 3H), 0.88 (s, 9H), 0.92–0.95 (m, 9H), 1.18 (td, J = 2.4, 12.6 Hz, 1H), 1.32–1.43 (m, 4H), 1.49–1.68 (m, 4H), 1.76–1.93 (m, 4H), 2.03–2.17 (m, 1H), 2.30–2.37 (m, 1H), 4.00–4.02 (m, 1H), 4.26 (dd, J = 3.6, 9.0 Hz, 1H), 4.37 (t, J = 9.0 Hz, 1H), 4.57 (dt, J = 3.9, 9.0 Hz, 1H), 5.96 (dd, J = 1.5, 49.2 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ –5.2, –4.9, 12.4 (d, J = 4.4 Hz), 13.7, 14.3, 17.6, 17.7, 17.9, 22.7, 25.0, 25.8, 28.0, 34.2, 37.1, 37.2, 40.6, 42.0, 52.7, 52.9, 57.7, 64.0, 69.3, 91.9 (d, J = 182.4 Hz), 153.4, 169.7 (d, J = 23.0 Hz); HRMS (ESI+) calcd for C26H46NO4FSiNa [M+Na]+ 506.3072, found 506.3091.
  • (2S,3S)-3-{(1R,3aR,4S,7aR)-4-[(tert-Butyldimethylsilyl)oxy]-7a-methyloctahydro-1H-inden-1-yl}-2-fluoro-N-methoxy-N-methylbutanamide (34)
To a solution of 29 (105.9 mg, 0.22 mmol) and Me(MeO)NH·HCl (48.8 mg, 0.50 mmol) in THF (10 mL) was added LHMDS (972 μL, 1 M in THF, 0.972 mmol) at 0 °C, and the mixture was stirred at the same temperature for 25 min. After the reaction was quenched with water and aqueous saturated NH4Cl, the mixture was extracted with EtOAc three times. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified via flash column chromatography on silica gel (hexane:EtOAc = 4:1) to obtain 34 (45.4 mg, 50%) as a colorless oil. The spectral data matched with those reported in the literature [8].
  • (2R,3S)-3-{(1R,3aR,4S,7aR)-4-[(tert-Butyldimethylsilyl)oxy]-7a-methyloctahydro-1H-inden-1-yl}-2-fluoro-N-methoxy-N-methylbutanamide (35)
To a solution of 33 (39.4 mg, 0.081 mmol) and Me(MeO)NH·HCl (17.2 mg, 0.18 mmol) in THF (5 mL) was added LHMDS (324 μL, 1 M in THF, 0.324 mmol) at 0 °C, and the mixture was stirred at the same temperature for 4 min. After the reaction was quenched with water and aqueous saturated NH4Cl, the mixture was extracted with EtOAc three times. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified via flash column chromatography on silica gel (hexane:EtOAc = 4:1) to obtain 35 (18.7 mg, 55%) as a colorless oil. The spectral data matched with those reported in the literature [8].

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biom14010037/s1. File S1: 1H and 13C NMR spectra of all new compounds 26, 27, 29, 30, and 33.

Author Contributions

Conceptualization, F.K. and A.K.; investigation, F.K. and S.M.; original draft preparation, F.K.; writing—review and editing, A.K.; supervision, A.K.; funding acquisition, F.K. and A.K. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported in part by Grants-in-Aid from the Japan Society for the Promotion of Science (No. 22K14688 to F.K. and No. 23K06029 to A.K.).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Kawagoe, F.; Mototani, S.; Kittaka, A. Design and synthesis of fluoro analogues of vitamin D. Int. J. Mol. Sci. 2021, 22, 8191. [Google Scholar] [CrossRef] [PubMed]
  2. Kawagoe, F.; Sugiyama, T.; Uesugi, M.; Kittaka, A. Recent developments for introducing a hexafluoroisopropanol unit into the vitamin D side chain. J. Steroid Biochem. Mol. Biol. 2018, 177, 250–254. [Google Scholar] [CrossRef] [PubMed]
  3. Kawagoe, F. Synthesis of new 26,26,27,27-tetrafluoro and 26,27-difluoro-25-hydroxyvitamin D3: The effects of the terminal fluorine atoms on affinity to VDR and CYP24A1-dependent metabolism. Chem. Pharm. Bull. 2023, 71, 717–723. [Google Scholar] [CrossRef] [PubMed]
  4. Kawagoe, F.; Mototani, S.; Yasuda, K.; Nagasawa, K.; Uesugi, M.; Sakaki, T.; Kittaka, A. Introduction of fluorine atoms to vitamin D3 side-chain and synthesis of 24,24-difluoro-25-hydroxyvitamin D3. J. Steroid Biochem. Mol. Biol. 2019, 195, 105477. [Google Scholar] [CrossRef] [PubMed]
  5. Kawagoe, F.; Mototani, S.; Yasuda, K.; Mano, H.; Sakaki, T.; Kittaka, A. Stereoselective synthesis of 24-fluoro-25-hydroxyvitamin D3 analogues and their stability to hCYP24A1-dependent catabolism. Int. J. Mol. Sci. 2021, 22, 11863. [Google Scholar] [CrossRef]
  6. Mototani, S.; Kawagoe, F.; Yasuda, K.; Mano, H.; Sakaki, T.; Kittaka, A. The first convergent synthesis of 23,23-difluoro-25-hydroxyvitamin D3 and its 24-hydroxy derivatives: Preliminary assessment of biological activities. Molecules 2022, 27, 5352. [Google Scholar] [CrossRef]
  7. Kawagoe, F.; Yasuda, K.; Mototani, S.; Sugiyama, T.; Uesugi, M.; Sakaki, T.; Kittaka, A. Synthesis and CYP24A1-dependent metabolism of 23-fluorinated vitamin D3 analogues. ACS Omega 2019, 4, 11332–11337. [Google Scholar] [CrossRef]
  8. Kawagoe, F.; Mototani, S.; Yasuda, K.; Takeuchi, A.; Mano, H.; Kakuda, S.; Saitoh, H.; Sakaki, T.; Kittaka, A. Synthesis of (22R)-, (22S)-22-fluoro-, and 22,22-difluoro-25-hydroxyvitamin D3 and effects of side-chain fluorination on biological activity and CYP24A1-dependent metabolism. J. Org. Chem. 2023, 88, 12394–12408. [Google Scholar] [CrossRef]
  9. Nagata, A.; Akagi, Y.; Asano, L.; Kotake, K.; Kawagoe, F.; Mendoza, A.; Masoud, S.S.; Usuda, K.; Yasui, K.; Takemoto, Y.; et al. Synthetic chemical probes that dissect vitamin D activities. ACS Chem. Biol. 2019, 14, 2851–2858. [Google Scholar] [CrossRef]
  10. Kawagoe, F.; Mendoza, A.; Hayata, Y.; Asano, L.; Kotake, K.; Mototani, S.; Kawamura, S.; Kurosaki, S.; Akagi, Y.; Takemoto, Y.; et al. Discovery of a vitamin D receptor-silent vitamin D derivative that impairs sterol regulatory element-binding protein in vivo. J. Med. Chem. 2021, 64, 5689–5709. [Google Scholar] [CrossRef]
  11. Kawagoe, F.; Mototani, S.; Mendoza, A.; Takemoto, Y.; Uesugi, M.; Kittaka, A. Structure-activity relationship studies on vitamin D-based selective SREBP/SCAP inhibitor KK-052. RSC Med. Chem. 2023, 14, 2030–2034. [Google Scholar] [CrossRef]
  12. Sakaki, T.; Sawada, N.; Komai, K.; Shiozawa, S.; Yamada, S.; Yamamoto, K.; Ohyama, Y.; Inouye, K. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur. J. Biochem. 2000, 267, 6158–6165. [Google Scholar] [CrossRef] [PubMed]
  13. Sakaki, T.; Kagawa, N.; Yamamoto, K.; Inouye, K. Metabolism of vitamin D3 by cytochromes P450. Front. Biosci. 2005, 10, 119–134. [Google Scholar]
  14. Yasuda, K.; Nishikawa, M.; Okamoto, K.; Horibe, K.; Mano, H.; Yamaguchi, M.; Okon, R.; Nakagawa, K.; Tsugawa, N.; Okano, T.; et al. Elucidation of metabolic pathways of 25-hydroxyvitamin D3 mediated by Cyp24A1 and Cyp3A using Cyp24a1 knockout rats generated by CRISPR/Cas9 system. J. Biol. Chem. 2021, 296, 100668. [Google Scholar] [CrossRef] [PubMed]
  15. Kobayashi, Y.; Taguchi, T.; Terada, T.; Oshida, J.-I.; Morisaki, M.; Ikekawa, N. Synthesis of 24,24-difluoro- and 24ξ-fluoro-25-hydroxyvitamin D3. Tetrahedron Lett. 1979, 20, 2023–2026. [Google Scholar] [CrossRef]
  16. Shiuey, S.-J.; Partridge, J.J.; Chadha, N.K.; Boris, A.; Uskoković, M.R. Stereospecific synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol (Ro23-0233). In Vitamin D, Chemical, Biochemical and Clinical Update; Walter de Gruyter: Berlin, Germany, 1985; pp. 765–766. [Google Scholar]
  17. Shiuey, S.-J.; Partridge, J.J.; Uskoković, M.R. Triply convergent synthesis of 1α,25-dihydroxy-24(R)-fluorocholecalciferol. J. Org. Chem. 1988, 53, 1040–1046. [Google Scholar] [CrossRef]
  18. Yamada, S.; Ohmori, M.; Takayama, H. Synthesis of 24,24-difluoro-25-hydroxyvitamin D3. Tetrahedron Lett. 1979, 20, 1859–1862. [Google Scholar] [CrossRef]
  19. Gill, H.S.; Londowski, J.M.; Corradino, R.A.; Zinsmeister, A.R.; Kumar, R. Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1α,25-dihydroxy-26,27-dimethylvitamin D3. J. Med. Chem. 1990, 33, 480–490. [Google Scholar] [CrossRef]
  20. Konno, K.; Ojima, K.; Hayashi, T.; Takayama, H. An alternative and efficient synthesis of 24,24-difluoro-1α,25-dihydroxyvitamin D3. Chem. Pharm. Bull. 1992, 40, 1120–1124. [Google Scholar] [CrossRef]
  21. Ando, K.; Kondo, F.; Koike, F.; Takayama, H. An improved synthesis of 24,24-difluoro-1α,25-dihydroxyvitamin D3 from vitamin D2. Chem. Pharm. Bull. 1992, 40, 1662–1664. [Google Scholar] [CrossRef]
  22. Kondo, F.; Maki, S.; Konno, K.; Takayama, H. The first synthesis of 24,24-difluoro-1α-hydroxyvitamin D3 by means of radical deoxygenation of alcohols. Chem. Pharm. Bull. 1996, 44, 62–66. [Google Scholar] [CrossRef]
  23. Iwasaki, H.; Hosotani, R.; Miyamoto, Y.; Nakano, Y.; Yamamoto, K.; Yamada, S.; Shinki, T.; Suda, T.; Yamaguchi, K.; Konno, K.; et al. Stereoselective synthesis and structural establishment of (25S)-24,24-difluoro-1α,25,26-trihydroxyvitamin D3, a major metabolite of 24,24-difluoro-1α,25-dihydroxyvitamin D3. Tetrahedron 1998, 54, 14705–14724. [Google Scholar] [CrossRef]
  24. Flores, A.; Massarelli, I.; Thoden, J.B.; Plum, L.A.; DeLuca, H.F. A methylene group on C-2 of 24,24-difluoro-19-nor-1α,25-dihydroxyvitamin D3 markedly increases bone calcium mobilization in nivo. J. Med. Chem. 2015, 58, 9731–9741. [Google Scholar] [CrossRef] [PubMed]
  25. Tanaka, Y.; DeLuca, H.F.; Schnoes, H.K.; Ikekawa, N.; Kobayashi, Y. 24,24-difluoro-1,25-dihydroxyvitamin D3: In vitro production, isolation, and biological activity. Arch. Biochem. Biophys. 1980, 199, 473–478. [Google Scholar] [CrossRef] [PubMed]
  26. Gill, H.S.; Londowski, J.M.; Corradino, R.A.; Kumar, R. The synthesis and biological activity of 22-fluorovitamin D3: A new vitamin D analog. Steroids 1986, 48, 93–108. [Google Scholar]
  27. Davis, F.A.; Kasu, P.V.N. Asymmetric synthesis of α-fluoro ketones using α-fluoro oxazolidinone carboximides. Tetrahedron Lett. 1998, 39, 6135–6138. [Google Scholar] [CrossRef]
  28. Less, S.L.; Handa, S.; Millburn, K.; Leadlay, P.F.; Dutton, C.J.; Staunton, J. Biosynthesis of Tetronasin: Part 6. Preparation of structural analogues of the diketide and triketide biosynthetic precursors to Tetronasin. Tetrahedron Lett. 1996, 37, 3515–3518. [Google Scholar] [CrossRef]
  29. Brunet, V.A.; O’Hagan, D.; Slawin, A.M.Z. Titanium mediated asymmetric aldol reaction with α-fluoropropionimide enolates. J. Fluor. Chem. 2007, 128, 1271–1279. [Google Scholar] [CrossRef]
  30. Mascareñas, J.L.; Pérez-Sestelo, J.; Castedo, L.; Mouriño, A. A short, flexible route to vitamin D metabolites and their side chain analogues. Tetrahedron Lett. 1991, 32, 2813–2816. [Google Scholar] [CrossRef]
  31. Nicoletti, D.; Mouriño, A.; Torneiro, M.S. Synthesis of 25-hydroxyvitamin D3 and 26,26,26,27,27,27-hexadeutero-25-hydroxyvitamin D3 on solid support. J. Org. Chem. 2009, 74, 4782–4786. [Google Scholar] [CrossRef]
  32. Yu, O.B.; Mutchie, T.R.; Di Milo, E.S.; Arnold, L.A. Synthesis and biological evaluation of calcioic acid. Steroids 2020, 154, 108536. [Google Scholar] [CrossRef]
Scheme 1. Convergent synthesis of side-chain fluorinated vitamin D3 analogues via side-chain fluoro-CD-ring fragments (2–13) starting from the Inhoffen–Lythgoe diol (1).
Scheme 1. Convergent synthesis of side-chain fluorinated vitamin D3 analogues via side-chain fluoro-CD-ring fragments (2–13) starting from the Inhoffen–Lythgoe diol (1).
Biomolecules 14 00037 sch001
Figure 1. Structures of side-chain fluorinated CD-rings (2–13).
Figure 1. Structures of side-chain fluorinated CD-rings (2–13).
Biomolecules 14 00037 g001
Scheme 2. Synthetic route to C24-fluoro-CD-rings (5,6) using dihydroxylation/deoxyfluorination reactions.
Scheme 2. Synthetic route to C24-fluoro-CD-rings (5,6) using dihydroxylation/deoxyfluorination reactions.
Biomolecules 14 00037 sch002
Scheme 3. Preparation of C22-fluoro-CD-rings (11,12) using DAST for the deoxyfluorination step.
Scheme 3. Preparation of C22-fluoro-CD-rings (11,12) using DAST for the deoxyfluorination step.
Biomolecules 14 00037 sch003
Scheme 4. Electrophilic fluorination at the C22-position of the CD-ring side-chain.
Scheme 4. Electrophilic fluorination at the C22-position of the CD-ring side-chain.
Biomolecules 14 00037 sch004
Scheme 5. Synthetic plans for the C24- and C22-fluoro-CD-rings (5,6,11). * means a chiral center.
Scheme 5. Synthetic plans for the C24- and C22-fluoro-CD-rings (5,6,11). * means a chiral center.
Biomolecules 14 00037 sch005
Scheme 6. Improved synthesis of 24-fluoro-CD-rings (5,6) via electrophilic fluorination [30,31].
Scheme 6. Improved synthesis of 24-fluoro-CD-rings (5,6) via electrophilic fluorination [30,31].
Biomolecules 14 00037 sch006
Scheme 7. Improved synthesis of (22R)-fluoro-CD-ring (11) [32].
Scheme 7. Improved synthesis of (22R)-fluoro-CD-ring (11) [32].
Biomolecules 14 00037 sch007
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kawagoe, F.; Mototani, S.; Kittaka, A. Efficient Stereo-Selective Fluorination on Vitamin D3 Side-Chain Using Electrophilic Fluorination. Biomolecules 2024, 14, 37. https://doi.org/10.3390/biom14010037

AMA Style

Kawagoe F, Mototani S, Kittaka A. Efficient Stereo-Selective Fluorination on Vitamin D3 Side-Chain Using Electrophilic Fluorination. Biomolecules. 2024; 14(1):37. https://doi.org/10.3390/biom14010037

Chicago/Turabian Style

Kawagoe, Fumihiro, Sayuri Mototani, and Atsushi Kittaka. 2024. "Efficient Stereo-Selective Fluorination on Vitamin D3 Side-Chain Using Electrophilic Fluorination" Biomolecules 14, no. 1: 37. https://doi.org/10.3390/biom14010037

APA Style

Kawagoe, F., Mototani, S., & Kittaka, A. (2024). Efficient Stereo-Selective Fluorination on Vitamin D3 Side-Chain Using Electrophilic Fluorination. Biomolecules, 14(1), 37. https://doi.org/10.3390/biom14010037

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop